Donepezil for mild cognitive impairment in Parkinson’s disease

We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Baik, Kyoungwon, Kim, Seon Myeong, Jung, Jin Ho, Lee, Yang Hyun, Chung, Seok Jong, Yoo, Han Soo, Ye, Byoung Seok, Lee, Phil Hyu, Sohn, Young H., Kang, Seung Wan, Kang, Suk Yun
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7910590/
https://ncbi.nlm.nih.gov/pubmed/33637811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-84243-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky